Application Note

Antibody Drug Conjugate (ADC) Separation Using A Mixed Mode Cation Exchange Chromatography Step In A Monoclonal Antibody (mAb) Process

Millipore

This application note provides a description of the steps followed and considerations taken during the development of antibody drug conjugate separation using a mixed mode cation exchange chromatography step.

Antibody drug conjugates (ADC) is a new class of high potency drugs dedicated to cancer treatment. Whereby the antibody molecule is dedicated for the specific recognition of cancer cells, the toxic payload carried by the antibody molecule destroys them (Adcetris®, Kadcyla®). These new drugs are manufactured by conjugating a toxic molecule (payload) on the monoclonal antibody (mAb) molecule and is achieved through controlled chemical conjugation with specific amino acid residues exposed on the surface of the mAb (for example: Lysine or Cysteine after cysteine bond reduction) that results into a heterogeneous mixture of ADC species with variable drug to antibody ratio (DAR).

VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: